Introduction {#S1}
============

Major depressive disorder (MDD) is a severe and a common mental illness affecting more than 264 million people worldwide ([@B37]). The World Health Organization (WHO) describes depression, also indicated as MDD or clinical depression, as a mental disorder characterized by sleep and appetite disturbances, variation of mood, loss of energy, and psychomotor retardation^[1](#footnote1){ref-type="fn"}^.

Among the different hypotheses that have been proposed to explain MDD pathophysiology, the "monoaminergic hypothesis" has been initially validated with the development of monoaminergic antidepressants. Based on this hypothesis an impairment of monoaminergic systems \[serotonin (5-HT), noradrenaline, and dopamine\] has been considered a primary event for the onset of affective and cognitive symptoms in MDD ([@B45]; [@B40]). Therefore, the majority of antidepressant drugs have been developed according to this hypothesis, representing a useful therapeutic tool ([@B54]); unfortunately around 30% of depressed patients are considered treatment resistant ([@B19]), probably because emerging additional factors involved in the pathophysiology of MDD, such as chronic stress and neuroinflammation, should be considered ([@B20]). The pathological effects of stress on hippocampus have contributed to the development of the so-called "neurotrophic hypothesis" according to which neurotrophic factors play a key role in the etiology of depression ([@B3]; [@B30]; [@B47]). This hypothesis suggests that depression derives from decreased neurotrophic support resulting in neuronal atrophy, decreased hippocampal neurogenesis, and loss of glial cells ([@B31]). A hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis has been found in the 50% of depressed patients ([@B51]) and several evidences identify chronic stress, linked to an impairment of neurotrophins such as brain-derived neurotrophic factor (BDNF) and transforming-growth-factor-β1 (TGF-β1) ([@B20]), as a risk factor for the development of MDD ([@B74]; [@B21]). A significant decrease of BDNF levels has been demonstrated in animal models of depression stress-induced ([@B10]) as well as in depressed patients ([@B4]). Likewise, a decrease of TGF-β1 levels has been observed in hippocampus and cortex of animal models of depression ([@B100]); furthermore, several studies carried out in depressed patients have demonstrated that plasma TGF-β1 levels are reduced and correlate with depression severity ([@B66]; [@B79]). A chronic treatment with first- and second-generation antidepressants rescues BDNF levels in different preclinical models of depression ([@B31]), while selective serotonin reuptake inhibitors (SSRIs) drugs and the new multimodal antidepressant vortioxetine are able to reverse the depressive-like phenotype and memory deficits induced by amyloid-β (Aβ) in mice by the rescue of TGF-β1 ([@B90]). Furthermore, antidepressant drugs exert immunoregulatory effects reducing the production of pro-inflammatory cytokines and stimulating the synthesis of TGF-β1 in depressed patients ([@B86]).

Noteworthy, it has been shown that epigenetic mechanisms such as DNA methylation, microRNAs, and histone modifications are able to influence the development of depression ([@B53]) and, with specific regard to BDNF, their altered activity can in turn affect the expression and the activity of this neurotrophic factor ([@B44]).

Several studies have demonstrated that aerobic exercise (AE) could represent a non-pharmacological strategy to improve the treatment of depression, decreasing, at the same time, the burden of somatic comorbidity of this pathology ([@B62]; [@B48]). Since the 1980s, several papers have reported on the beneficial effects played by exercise and physical activity in the treatment of depression, effects comparable to those of antidepressants ([@B59]; [@B7]; [@B8]; [@B55]). This increased interest in this field has led to the proposal that physical exercise may serve as an alternative or integrative approach in combination with monoaminergic drugs for the treatment of MDD ([@B58]).

In the present review we will provide a general overview on the possible synergism between physical activity and antidepressants in treatment of MDD, analyzing the possible benefits of physical activity both at a neurobiological level and clinical level focusing in particular on the treatment of affective and cognitive symptoms in MDD.

The Pathophysiology of Depression: the Role of Neurotrophic Factors and the Possible Impact of Physical Activity {#S2}
================================================================================================================

MDD shows a complex pathophysiology that has been only partially elucidated in the last 10 years ([@B19]). Chronic stress, reduced synaptic plasticity, impairment of adult hippocampal neurogenesis, and hippocampal neurodegeneration along with the well-known dysregulation of the monoaminergic system contribute to explain the pathophysiology of MDD ([@B47]; [@B95]). Epidemiological studies support the pivotal role played by chronic stress in MDD ([@B74]); in fact, the exposure to stressful life events contributes to the development of this disease ([@B27]). Chronic stress leads to an impaired negative feedback of glucocorticoids (GR) on the activity of HPA axis, which results in elevated cortisol levels ([@B28]). Excess of GR is able to induce neuronal death at hippocampal level ([@B99]) as well as dysfunctional changes in the prefrontal cortex (PFC), two regions critically involved in the cognitive symptoms of depression ([@B51]). Stress also exerts its effects by reducing the synthesis of factors essential for neuronal homeostasis such as BDNF ([@B72]), a neurotrophin fundamental for the maintenance of dendritic spines ([@B93]), the regulation of adult hippocampal neurogenesis ([@B94]), cognitive and mood-related behavior and aging ([@B24]). Reduced levels of BDNF have been connected to dendritic atrophy, neuronal apoptosis, and inhibition of neurogenesis in MDD ([@B72]). Stress decreases BDNF concentrations in hippocampus and PFC of animal models of depression ([@B84]; [@B31]; [@B36]), in line with the reduced expression of this neurotrophic factor observed at cortical, hippocampal, and peripheral level of depressed patients ([@B89]; [@B76]). Stress exposure also leads to an impairment of TGF-β1 signaling in different brain regions (hippocampus, cortex, and hypothalamus) ([@B98]; [@B22]). This impairment has been connected to the onset of a depressive-like phenotype in mice ([@B90]). Lastly, a correlation between reduced TGF-β1 plasma levels, depression severity, and treatment resistance in MDD has been proved ([@B86]; [@B19]).

In addition to HPA axis hyperactivation, immune system dysregulation and neuroinflammation play a central role in the pathophysiology of depression ([@B21]), underlining the great impact of immune system activation on the central nervous system and in particular on the overall activity of monoaminergic systems ([@B19]). An increase of two well-known pro-inflammatory cytokines, called interleukin (IL)-1β and tumor necrosis factor-α (TNF-α), as well as a decrease of anti-inflammatory cytokines (e.g., IL-10, IL-4, and TGF-β1) have been observed in hippocampus and cortex of animal models of depression ([@B98]) and MDD patients ([@B35]; [@B23]).

Antidepressant drugs, such as sertraline and fluoxetine, exert immunomodulatory effects, reducing the production of pro-inflammatory cytokines and stimulating the synthesis of TGF-β1 in depressed patients ([@B86]; [@B57]; [@B19]). Furthermore, the ability of some antidepressant drugs to induce the synthesis and the release of BDNF and TGF-β1 has been demonstrated both *in vitro* and *in vivo* studies ([@B21]), suggesting that the long time required for BDNF restore could, at least in part, contributes to explain the therapeutic latency (2--4 weeks) of these drugs ([@B75]). Recent studies have demonstrated the rapid and long-lasting antidepressant effects of TGF-β1 as well as the key role of TGF-β1 released from microglia in mediating the antidepressant activity of (R)-ketamine (10 mg/kg) in a mouse model of depression ([@B101]). (R)-ketamine is a novel drug under study for treatment-resistant MDD patients. Interestingly this drug rescued the expression of TGF-β1 and its receptors in the PFC and hippocampus, whereas inhibition of TGF-β1 signaling (i.e., SB431542) or neutralizing antibody of TGF-β1 blocked the antidepressant effects of (R)-ketamine, thus suggesting the essential and novel role of TGF-β1 as antidepressant.

According to the neurotrophic hypothesis of depression, which could be the impact of physical activity on the neurobiology of depression considering recent evidence in MDD patients?

Physical activity as an add-on strategy to the traditional treatment of depression is able to reduce the relapse risk, increase adherence to pharmacological treatment, and promote the management of side effects with a 60--80% of success ([@B69]; [@B82]; [Figure 1](#F1){ref-type="fig"}).

![Physical activity as an add-on treatment strategy to antagonize stress-induced depression.](fpsyg-11-00857-g001){#F1}

Interestingly a recent study conducted by [@B64], has demonstrated that physical exercise, in combination with the SSRI sertraline, reduces affective symptoms and psychomotor retardation in MDD. Furthermore, the beneficial effects of AE as an add-on strategy in the treatment of moderate to severe depression has been shown in a study carried out by [@B46], considering different psychological and biological variables (e.g., BDNF, HPA axis activity, cognitive symptoms) besides depression severity.

Physical activity exerts beneficial effects on pre- and postnatal brain development ([@B38]), stimulates neurogenesis and synaptic plasticity by increasing BDNF synthesis and release ([@B96]), and reduces HPA axis hyperactivation ([@B67]). In particular, it has been proposed, as a proof of muscle-brain crosstalk, that irisin, produced during exercise through the cleavage of fibronectin type III domain-containing protein 5 (FNDC5) membrane protein and able to cross the blood-brain barrier, induces BDNF expression at brain level, which in turn will lead to an increased hippocampal neurogenesis, and therefore to enhanced learning, memory, and mood ([@B73]). With regard to TGF-β1, the plasma concentration of this neurotrophin increases in response to exercise (1 h of treadmill running) ([@B42]). In a different study enrolling healthy people and Parkinson subjects, the immunomodulatory effects of moderate intensity on plasma neurotrophins levels was investigated ([@B87]). [@B87] demonstrated that after completion of the 12 weeks training program the concentration of TGF-β1 as well as of other neurothophic factors (nerve growth factor and BDNF) were found to be increased only in training groups. Furthermore, in a study considering a total of 29 athletes, the serum levels of TGF-β1 were higher in athletes with high relative Vo~2~peak (relVo~2~peak) values, a measure of the athletes' cardiovascular fitness and aerobic endurance, compared to low relVo~2~peak ([@B97]). No studies have been conducted yet in MDD patients to assess whether SSRIs can synergize with AE to increase TGF-β1 signaling, although preliminary available evidence suggests the existence of common biological targets.

All together, the above mentioned evidence suggests a synergistic effect between AE and antidepressant drugs for the treatment of depression ([Figure 2](#F2){ref-type="fig"}), reducing the cognitive deficits that compromise the working activities of MDD patients and influence their relapse risk ([@B2]). This synergism might be particularly relevant in elderly patients with late-life depression (LLD), a clinical sub-group with an increased risk to develop dementia, improving patients' cognitive outcomes ([@B70]).

![Synergic effect between physical activity and antidepressants: positive modulation of neurotrophic factors.](fpsyg-11-00857-g002){#F2}

Impact of Physical Activity on Affective Symptoms in MDD {#S3}
========================================================

Apart from biological and genetic risk factors ([@B39]), physical inactivity has been identified as a risk factor for the development of depression ([@B1]; [@B39]). Along this line different studies have shown that physical activity is able to provide mental health benefits in patients with severe mental illness, reducing depressive symptoms and improving social and cognitive functions ([@B78]). In a recent global systematic review and meta-analysis including 69 studies, [@B91] have examined sedentary behavior and levels of physical activity in patients with MDD or other severe mental disorders. After the analysis of the studies, it was clear as the physical activity was connected to health benefits in healthy controls while the level of activity as well as the related benefits were low in people with severe mental illnesses ([@B91]). Indeed, as confirmed in different studies, regular physical activity of moderate intensity, such as walking or cycling, is enough to give significant benefits for health and plays a protective role in preventing different mental disorders ([@B5]); whereas lack of exercise represents a major cause of chronic diseases, including depression ([@B14]). Several studies have focused their attention on the potential benefits of physical activity to prevent the development of this disease. The "HUNT Cohort Study" investigated whether exercise provides protection against new-onset depression, the importance of both intensity and amount of physical activity and existing associations between them ([@B41]). The results based on a healthy cohort of 33,908 adults followed for 11 years suggested that regular leisure-time exercise of any intensity provides protection against future depression development. Very recently [@B9] showed in a study employing a large sample (23,635) of German adults that AE is associated with a lower likelihood of depressive symptoms severity, as assessed by eight-item Patient Health Questionnaire depression scale (PHQ-8). In a case report published by [@B18], AE was able to improve physical conditions and to dramatically decrease depressive symptoms (sadness, anhedonia, reluctance to getting out of house, memory complaints) in a 76 years old female patient. Before enrollment in the study, she followed a 6-months treatment with antidepressants without getting any improvement. She followed a special 4-weeks exercise program consisting of 10 min warm-up (jogging, breathing, upper, and lower extremity active exercises), 20--25 min flexibility, balance and strengthening exercise, and 10 min cool-down exercise periods.

It has been shown that regular physical activity is able to reduce sleep disturbances ([@B26]) and improve somatic, affective, and cognitive symptoms in depressed patients, especially by enhancing the psychological health and social relationships ([@B7]). [@B68], by the analysis of different randomized controlled trials in which physical exercise and pharmacologic treatment were compared, found in all studies considered, except one, that patients performing physical activity as an adjunctive treatment for depression have a significant improvement of depressive symptoms and a better clinical response after the exercise period.

An additional meta-analysis, carried out by [@B52], shows as different types of exercise (e.g., walking, running, cycling) could represent a viable adjunct treatment in combination with antidepressants. They demonstrate that the effects of exercise as an independent treatment were evident, with maximum efficacy showed when compared to no intervention, suggesting that physical activity may represent an alternative approach in non-responder patients.

As discussed above, a regular physical activity is also able to reduce depressive symptoms by different neurobiological mechanisms. In fact, it can increase monoaminergic neurotransmission ([@B85]), reduce cortisol levels simultaneously increasing hippocampal neurogenesis ([@B77]; [@B11]; [@B71]), and increase β-endorphin and BDNF levels ([@B33]). Since in the brain, neurons are a significant source of BDNF, whose synthesis occurs in regions fundamental for emotional and cognitive functions ([@B80]), these preliminary evidence suggests that physical activity, when performed in combination with pharmacological antidepressant treatment, may improve affective symptoms in MDD patients.

Impact of Physical Exercise on Cognitive Symptoms in MDD {#S4}
========================================================

MDD could be considered as the most common mental illness among elderly people with an estimated prevalence ranging from 4.6 to 9.3% ([@B56]). Rates of MDD are by and large lower in healthy community-dwelling elderly people than in younger adult populations, in a range from 1 to 3% ([@B49]). However, these rates can increase on the basis of increasing medical and psychiatric comorbidity as well as in relation to various social conditions ([@B34]). LLD, occurring in people with an age ≥60 years, is often associated to cognitive dysfunction ([@B88]). Cognitive dysfunction can affect one or multiple cognitive domains such as attention, working memory, verbal fluency, visuospatial abilities, and executive function ([@B65]). Furthermore, this clinical sub-group presents a higher risk to develop dementia, in particular Alzheimer's disease and vascular dementia ([@B21]; [@B29]). LLD clinical manifestations are individual suffering, increased morbidity, premature mortality, and greater healthcare utilization ([@B29]; [@B60]), compromising the geriatric patients' life quality ([@B61]). Moreover, LLD is a condition often accompanied by significant impairment in physical and social functioning as well as disability ([@B12]; [@B25]). Longitudinal studies have shown that LLD worsens the outcomes of physical illnesses and the likelihood of frailty in elderly people ([@B17]; [@B92]). Research community has focused its attention on physical exercise as a potential non-pharmacological treatment to improve cognitive function in depressed elderly patients. Since 1990s, several studies have been carried out to demonstrate the efficacy of physical exercise as an intervention for clinical depression in these patients ([@B32]; [@B13]). In a randomized controlled trial, [@B83] demonstrated the effectiveness of a 20 weeks physical exercise program as a long-term treatment for clinical depression in elderly patients. The same year, in a different study, the effectiveness of a structured exercise program on specific areas of cognitive functioning (e.g., attention, concentration, executive processes, figural memory) compared to antidepressants treatment has been proved ([@B50]). In 2012, [@B16] showed that structured physical exercise tailored to individual ability reduces depression severity in older people with clinically significant symptoms of depression. More recently, [@B43] demonstrated that all investigated types of physical exercise, such as AE, resistance training, dancing, and alternative forms of exercise (Qi Gong and Tai Chi), may serve as a feasible and additional intervention for depression in elderly people. This preliminary evidence was strengthen by a meta-analysis of randomized controlled trials carried out by [@B81], suggesting that previous meta-analyses have underestimated the benefits of exercise and therefore structural physical exercise should be considered as a routine component of the management of depression in older adults.

This evidence shows how physical exercise could improve the effectiveness of pharmacological treatments in elderly depressed patients ([@B62]; [@B63]). An improvement in memory and executive functions that persists for up to 24 months was demonstrated in elderly depressed patients who followed an integrative approach consisting of combined physical activity and pharmacological treatment ([@B15]). [@B63], in a study of 24 weeks employing 121 primary care patients (\>65 years) with major depression, demonstrated the synergism between the antidepressant sertraline and two different types of physical exercise in improving the outcomes related to LLD. In particular, a higher remission rate (primary outcome) was observed for the higher intensity, progressive AE plus sertraline group (81%), showing an increment of +8% (and shorter time to remission) and +36% compared to lower-intensity, non-progressive exercise plus antidepressant and sertraline alone, respectively.

[@B70] performed secondary analyses on data from the Safety and Efficacy of Exercise for Depression in Seniors study, a trial comparing the effectiveness of sertraline, in the absence or in the presence of progressive or non-progressive exercise. The results of 121 patients (mean age 75 years) showed improvements of Montreal Cognitive Assessment (MoCA) total scores and visuospatial/executive functions for sertraline plus progressive exercise group, showing how the addition of aerobic, progressive exercise to antidepressant drug treatment may offer significant advantages over standard treatment with regard to cognitive abilities and disability ([@B70]).

Conclusion {#S5}
==========

Physical activity stimulates neurogenesis and synaptic plasticity through BDNF synthesis and release, induces physiological changes in endorphine and monoamine levels, increases the plasma concentration of TGF-β1, and reduces cortisol levels; it can also act as an "anti-inflammatory factor" increasing IL-10 levels and suppressing TNF-α production, thus exerting "antidepressant-like effects". Therefore, we can assert that physical activity modulates many mechanisms and systems involved in the pathophysiology of depression. Physical activity has also proved able to act on the core symptoms of depression, decreasing sadness, anhedonia, and sleep disturbances, improving metabolic control and cognitive functions such as attention and concentration, and also decreasing the risk of depression and dementia development. Lastly, different clinical trials have highlighted the effects of physical activity as add-on treatment for MDD patients with moderate to severe depression, underlining the existing synergism between AE and the traditional pharmacological treatment. This synergism might be particularly relevant in elderly patients with LLD, a clinical sub-group characterized by an increased risk to develop dementia.
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